Delivery of neoadjuvant chemoradiation for patients with stage II and III rectal cancer is suboptimal

Publisher： John Wiley & Sons Inc

E-ISSN： 1542-4863|66|5|357-358

ISSN： 0007-9235

Source： CA: A CANCER JOURNAL FOR CLINICIANS, Vol.66, Iss.5, 2016-09, pp. : 357-358

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 2, 2015-02 ,pp. : 243-247

John Wiley & Sons Inc

Access to resources Recommend Favorite

Can Dynamic MR Imaging Predict Response in Patients with Rectal Cancer Undergoing Cetuximab-Based Neoadjuvant Chemoradiation?

By  

Oncology Research and Treatment, Vol. 32, Iss. 3, 2009-02 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: Is it necessary for all patients?

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 4, 2015-04 ,pp. : 439-444

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic factors for low rectal cancer patients undergoing intersphincteric resection after neoadjuvant chemoradiation

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 8, 2015-06 ,pp. : 1054-1058

John Wiley & Sons Inc

Access to resources Recommend Favorite

Microsatellite Instability Did Not Predict Individual Survival in Sporadic Stage II and III Rectal Cancer Patients

By  

Oncology, Vol. 72, Iss. 1-2, 2007-11 ,pp. : 82-88

Karger

Access to resources Recommend Favorite